BunneyMH, NolanMW, WilliamsDA: An assessment of methods of treating viral warts by comparative treatment trials based on a standard design. Br J Dermatol94: 667, 1976.10.1111/j.1365-2133.1976.tb05167.x820365)| false
CliftonMM, JohnsonSM, RobersonPK, et al: Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. Pediatr Dermatol20: 268, 2003.10.1046/j.1525-1470.2003.20318.x)| false
KimKH, HornTD, PharisJ, et al: Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol146; 12. 2010.10.1001/archdermatol.2010.350http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000285467500024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f321173332)| true
MaronnM, SalmC, LyonV, et al: One year experience with Candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol25: 189, 2008.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000255213500009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f31842977610.1111/j.1525-1470.2008.00630.x)| true
Candida albicans Immunotherapy for Verrucae Plantaris
Tracey C. Vlahovic
Tracey C. VlahovicTemple University School of Podiatric Medicine, Philadelphia, PA. Dr. Ghosh is now with St. Luke's Hospital, Allentown, PA. Dr. Tran is now with Metrowest Medical Center, Framingham, MA.
Verrucae plantaris is a viral disease caused by human papilloma virus that is commonly seen in the office setting and is often challenging to treat owing to its high recurrence rate and recalcitrant profile. Candida albicans intralesional injections have been hypothesized to incite an immunogenic response toward the virus.
We report on the immunotherapeutic effect of intralesional injection of C albicans into plantar verrucae with a retrospective medical record analysis of 80 patients. Using a luer-lock syringe, 0.1 to 0.3 mL of C albicans antigen was injected into either the first known lesion or the largest lesion.
The success rate of intralesional C albicans, defined as total clearance of the lesion, was 65%, which may be underestimated because patients lost to follow-up were included in the 35% failure rate. It was also found that female patients with a previous tissue-destructive treatment process were more than four times more likely to respond to C albicans therapy, whereas this effect was less pronounced in the male patient population.
These results indicate that a series of intralesional injections of C albicans is an effective and efficient method of treatment for verrucae plantaris.
Corresponding author: Tracey C. Vlahovic, DPM, Temple University School of Podiatric Medicine, 148 N 8th St, Philadelphia, PA 19107. (E-mail: firstname.lastname@example.org)